Epidemiology and treatment of pulmonary arterial hypertension

E-poster session
Chairs: S. Sahay (Houston, United States of America), E. Nossent (Amsterdam, Netherlands)

Drug-drug interaction study between zamicastat and sildenafil in healthy subjects A. Santos (Porto, Portugal), J. Ferreira (Porto, Portugal), H. Gama (Porto, Portugal), P. Magalhães (Porto, Portugal), P. Soares-Da-Silva (Porto, Portugal)
LTI-201: Evaluation of the hemodynamics and safety of inhaled LIQ861 (treprostinil) in pulmonary arterial hypertension (WHO Group 1) patients R. Roscigno (Morrisville, United States of America), M. Humbert (Le Kremlin-Bicêtre, France), T. Vaughn (Morrisville, United States of America), W. Seeger (Giessen, Germany), L. Savale (Le Kremlin-Bicêtre, France)
Inspiratory flow patterns with dry powder inhalers (DPIs) of low and medium flow resistance in subjects with pulmonary arterial hypertension (PAH) M. Faria Urbina (Boston, United States of America), K. Ung (San Francisco, United States of America), L. Zisman (San Diego, United States of America), A. Waxman (Boston, United States of America)
Inspiratory flow profiles of PAH patients with AOS™ device intended to administer inhaled vardenafil S. Sahay (Houston, United States of America), R. Holy (Houston, United States of America), S. Lyons (Burlingame, California, United States of America), E. Parsley (Burlingame, California, United States of America), M. Maurer (Burlingame, California, United States of America), J. Weers (Burlingame, California, United States of America)
Long-term survival in pulmonary hypertension with atrial septostomy: a single center experience R. Zebadua (Ciudad de Mexico, Mexico), T. Pulido (Ciudad de Mexico, Mexico), N. Zayas (Ciudad de Mexico, Mexico), J. Sandoval (Ciudad de Mexico, Mexico), J. Lopez (Ciudad de Mexico, Mexico), A. Garcia (Ciudad de Mexico, Mexico)
Macitentan in incident and prevalent pulmonary arterial hypertension (PAH): OPUS/OrPHeUS real-world data L. Melendres-Groves (Albuquerque, United States of America), R. Channick (Los Angeles, United States of America), K. Chin (Dallas, United States of America), V. Mclaughlin (Ann Arbor, United States of America), M. Flynn (South San Francisco, United States of America), R. Ong (Allschwil, Switzerland), G. Wetherill (Allschwil, Switzerland), N. Kim (La Jolla, United States of America)
Safety of macitentan in portopulmonary hypertension (PoPH): Real-world experience by liver transplant candidacy in the OPUS registry H. DuBrock (Rochester, United States of America), R. Channick (Los Angeles, United States of America), N. Kim (La Jolla, United States of America), V. Mclaughlin (Ann Arbor, United States of America), P. Agron (South San Francisco, United States of America), S. Leroy (Allschwil, Switzerland), G. Wetherill (Allschwil, Switzerland), K. Chin (Dallas, United States of America)
Long-term riociguat treatment towards implementing a targeted treatment strategy in patients with idiopathic pulmonary arterial hypertension A. Aleevskaya (Moscow, Russian Federation), S. Gratsianskaya (Moscow, Russian Federation), Z. Valieva (Moscow, Russian Federation), T. Martynyuk (Moscow, Russian Federation)
Loss of response to calcium channel blockers after long-term follow up in idiopathic pulmonary arterial hypertension B. Piloto (São Paulo (SP), Brazil), C. Fernandes (São Paulo (SP), Brazil), C. Jardim (São Paulo (SP), Brazil), M. Castro (São Paulo (SP), Brazil), W. Salibe-Filho (São Paulo (SP), Brazil), J. Alves-Jr (São Paulo (SP), Brazil), L. Morinaga (São Paulo (SP), Brazil), J. Sobral-Alves (São Paulo (SP), Brazil), S. Hoette (São Paulo (SP), Brazil), M. Terra-Filho (São Paulo (SP), Brazil), R. Souza (São Paulo (SP), Brazil)
Perioperative management of patients with Pulmonary Hypertension undergoing Non-Cardiac Surgery:  A Systemic Review and UK Consensus Statement L. Price (London, United Kingdom), A. Brame (London, United Kingdom), G. Martinez (Cambridge, United Kingdom), B. Mukerjee (London, United Kingdom), C. Harries (London, United Kingdom), A. Kempny (London, United Kingdom), P. Marino (London, United Kingdom), C. Church (Glasgow, United Kingdom), M. Johnson (Glasgow, United Kingdom), R. Condliffe (Sheffield, United Kingdom), D. Kiely (Sheffield, United Kingdom), R. Davies (London, United Kingdom), L. Howard (London, United Kingdom), G. Coghlan (London, United Kingdom), J. Lordan (Newcatle, United Kingdom), D. Taboada (Cambride, United Kingdom), T. Pickworth (London, United Kingdom), D. Alexander (London, United Kingdom), D. Wong (London, United Kingdom), A. Curry (Southamton, United Kingdom), S. Gaine (Ireland, Ireland), B. Garfield (London, United Kingdom), N. Reed (London, United Kingdom), S. Price (London, United Kingdom), S. Ledot (London, United Kingdom), K. Dimopoulos (London, United Kingdom), S. Wort (London, United Kingdom)
Perioperative management of patients with pulmonary hypertension in non-cardiac surgery, a retrospective study in a reference center n. cugnin (TOULOUSE, France), O. Mathe (TOULOUSE, France), G. Prevot (TOULOUSE, France), E. Noel Savina (TOULOUSE, France)
Sex bias exists in diagnosing pulmonary arterial hypertension via machine learning J. Uthoff (Sheffield, United Kingdom), S. Alabed (Sheffield, United Kingdom), P. Garg (Sheffield, United Kingdom), A. Lawrie (Sheffield, United Kingdom), J. Wild (Sheffield, United Kingdom), D. Kiely (Sheffield, United Kingdom), H. Lu (Sheffield, United Kingdom), A. Swift (Sheffield, United Kingdom)
Air pollution and pulmonary  arterial hypertension. Outcomes  in a referral center from Mexico City. T. Pulido Zamudio (México D.F, Mexico), D. Astorga (México D.F, Mexico), E. Diaz (México D.F, Mexico), A. Cruz (México D.F, Mexico), N. Zayas (México D.F, Mexico), J. Lopez (México D.F, Mexico), R. Zebadua (México D.F, Mexico), J. Sandoval (México D.F, Mexico)
Implementation of a systematic comprehensive geriatric assessment for elderly patients suspected of pulmonary hypertension L. Lafaie (Saint Etienne Cedex, France), C. Duvillard (Saint Etienne Cedex, France), E. De Magalhaers (Saint Etienne Cedex, France), S. Bezzeghoud (Saint Etienne Cedex, France), S. Accassat (Saint Etienne Cedex, France), P. Poble (Saint Etienne Cedex, France), P. Bonnefoy (Saint Etienne Cedex, France), C. Tulane (Saint Etienne Cedex, France), T. Celarier (Saint Etienne Cedex, France), L. Bertoletti (Saint Etienne Cedex, France)
Psychological disorders in patients with pulmonary arteriaI hypertension (Data from the PEPPAH-Study) T. Meltendorf (Hannover, Germany), K. Kahl (Hannover, Germany), H. Gall (Gießen, Germany), M. Richter (Gießen, Germany), J. Fuge (Hannover, Germany), M. Hoeper (Hannover, Germany), H. Ghofrani (Gießen, Germany, Germany), K. Olsson (Hannover, Germany)
LONG-TERM FOLLOW-UP OF PATIENTS WITH SYSTEMIC SCLEROSIS AND NORMAL OR BORDERLINE PULMONARY PRESSURES V. Dytrych (Prague, Czech Republic), D. Ambrož (Prague, Czech Republic), R. Becvár (Prague, Czech Republic), R. Hercíkova (Prague, Czech Republic), A. Linhart (Prague, Czech Republic), P. Jansa (Prague, Czech Republic)
BURDEN STUDY OF PULMONARY ARTERIAL HYPERTENSION AND CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION FOR COLOMBIA POPULATION D. Londoño (Bogotá, Colombia), C. Villaquirán (Bogotá, Colombia), R. Dueñas (Bogotá, Colombia), A. Taborda (Bogotá, Colombia), K. Rojas (Bogotá, Colombia), C. Chamorro (Bogotá, Colombia)
Quality of online information on pulmonary arterial hypertension. D. Saleh (Calgary, Canada), J. Fisher (Toronto, Canada), S. Provencher (Québec City, Canada), C. Ryerson (Vancouver, Canada), J. Weatherald (Calgary, Canada)
Impact of direct-acting antiviral (DAA) treatment for hepatitis C on pulmonary hemodynamics T. Orizaga Franco (Barcelona, Spain), I. Blanco Vich (Barcelona, Spain), S. Slens (Barcelona, Spain), E. Alvarado (Barcelona, Spain), Z. Mariño (Barcelona, Spain), X. Torras (Barcelona, Spain), A. Baiges (Barcelona, Spain), F. Turon (Barcelona, Spain), V. Hernández-Gea (Barcelona, Spain), C. Villanueva (Barcelona, Spain), J. Moises (Barcelona, Spain), X. Forns (Barcelona, Spain), J. García-Pagán (Barcelona, Spain), J. Barberà Mir (Barcelona, Spain)